key: cord-0958103-nswj8x43
authors: Vaisman-Mentesh, A.; Dror, Y.; Tur-Kaspa, R.; Markovitch, D.; Kournos, T.; Dicker, D.; Wine, Y.
title: SARS-CoV-2 specific memory B cells frequency in recovered patient remains stable while antibodies decay over time
date: 2020-08-25
journal: nan
DOI: 10.1101/2020.08.23.20179796
sha: a4ac1ad34382cfe4a582088946f68b7bb44735a1
doc_id: 958103
cord_uid: nswj8x43

The breadth of the humoral immune response following SARS-CoV-2 infection was indicated to be important for recovery from COVID-19. Recent studies have provided valuable insights regarding the dynamics of the antibody response in symptomatic COVID-19 patients. However, the information regarding the dynamics of the serological and cellular memory in COVID-19 recovered patients in scarce. It is imperative to determine the persistence of humoral memory in COVID-19 recovered patients as it will help to evaluate the susceptibility of recovered patients to re-infection. Here, we describe the dynamics of both the SARS-CoV-2 specific serological and B cell response in COVID-19 recovered patients. We found that symptomatic SARS-CoV-2 patients mount a robust antibody response following infection however, the serological memory decays in recovered patients over the period of 6 months. On the other hand, the B cell response as observed in the SARS-CoV-2 specific memory B cell compartment, was found to be stable over time. Moreover, the frequency of SARS-CoV-2 specific B cell plasmablasts was found to be associated with the SARS-CoV-2 specific antibody levels. These data, suggests that the differentiation of short-lived plasmablasts to become long-lived plasma cells is impaired and the main contributor of antibody production are the short-lived plasmablasts. Overall, our data provides insights regarding the humoral memory persistence in recovered COVID-19 patients. Notwithstanding the insights from this study, it is still to be determined if the persistence of SARS-CoV-2 memory B cells can be considered as a correlate of protection in the absence of serological memory.

-3 -

The first patients detected positive to coronavirus disease 2019 were identified in Wuhan, China 1 . These patients were found to be infected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leading to the declaration of the World Health Organization (WHO) that COVID-19 is a worldwide pandemic 2 . Rapid response to the outbreak provided important information regarding the virus genome sequence and especially the Spike protein (S protein) and its sub-region, the receptor binding domain (RBD) which is responsible for the binding to the human host cell receptor, human Angiotensin-converting enzyme 2 (hACE2) and mediates virus entry 3 . The S protein is highly immunogenic with the RBD holding the potential to elicit neutralizing antibodies (nAbs) 4 . The S protein RBD, was shown to elicit antibodies starting early as 3 days following the onset of symptoms 5 in which their levels increase along the progression of the disease [6] [7] [8] . Measuring RBD-specific serum antibody titers in samples collected from COVID-19 patients during active disease, suggests that in most cases, SARS-CoV-2 infection mounts a robust humoral response and generates antibodies specific to the S protein RBD 9 . Many serological studies are focused on developing diagnostic approaches for the detection of virus-specific antibodies by the identification of IgM and IgG antibodies as they are indicative of a productive progression of humoral immune response.

Serological tests for specific SARS-CoV-2 antibodies detection in patient's blood are important to trace contacts and for serological surveillance. Still the question remains if serological memory persist over time and recent studies suggest that the antibodies mounted against SARS-CoV-2 do not persist over time and decay several weeks following onset of symptoms 10 . At the cellular level, the T cell population was investigated as it was suggested that these cells may contribute to recovery 11 . T cell reactivity to SARS-CoV-2 epitopes was detected in non-exposed individuals suggesting a cross-reactive T cell recognition between circulating "common cold" coronaviruses and SARS-CoV-2 12 . The latter report further . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 25, 2020. . https://doi.org/10.1101/2020.08. 23.20179796 doi: medRxiv preprint strengthens the idea that memory wanes over time as the population does not develop immunity to common cold. On the other hand, SARS-CoV-2 specific T cells present in the general population may impact susceptibility and pathogenesis of SARS-CoV-2 infection 13, 14 .

Recent studies report on the isolation of RBD-specific B cells aiming at elucidating the composition of neutralizing antibodies using single cell analysis 15, 16 . However, the information regarding SARS-CoV-2 specific B cell dynamics is scarce and there is little information regarding the dynamics of antibodies and their association with the antigenspecific B cell compartment in COVID-19 recovered patients. This information is detrimental as it can help to evaluate the breadth of the humoral memory in COVID-19 recovered patients and to determine whither this will contribute for long-lasting serological and cellular memory.

Adaptive memory is two-parted, comprising long-lived antibody-secreting plasma cells (LLPC) which contribute to the serological memory and long-lived memory B cells (mBC) that have the capacity to react quickly to a recurrent antigenic challenge (cellular memory) 17 .

In this study we aim to understand the temporal dynamics of the serological and cellular memory in COVID-19 recovered patients.

To this end, we collected sera from 54 active COVID-19 patients and whole blood from 57 COVID-19 recovered patients and six follow up samples from the recovered cohort, along with their clinical data. Sera were tested to determine the levels of RBD-specific antibodies and their neutralization capacity. B cells isolated by FACS from COVID-19 recovered patients were used to determine the frequency of RBD-specific B cell subsets. We found that RBD-specific antibodies increase rapidly in symptomatic COVID-19 patients and further decline rapidly in recovered patients. We identified a strong correlation between the RBD-specific IgG levels and their neutralization capacity suggesting that RBD-specific antibody titer by itself may be used as a proxy to evaluate their neutralization capacity. Interestingly, we found that COVID-19 patients with metabolic disorder exhibit significant higher levels of RBD-specific antibodies. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 25, 2020. . https://doi.org/10.1101/2020.08. 23.20179796 doi: medRxiv preprint Additional association was found between the levels of RBD-specific antibodies with ferritin and C-reactive protein (CRP) indicating that disease severity leads to a robust immune response. More importantly, we found that there is a correlation between the time following onset of symptoms and the RBD-specific antibody titers indicating that the recovered COVID-19 patients experience a decay in their serological memory. In contrast to this decay, RBDspecific memory B cells were found to be stable within the range of six months following onset of symptoms. Overall, our data obtained in this study reveals a discordance between serological and cellular memory in COVID-19 recovered patients which has important implications on reinfection susceptibility and vaccine design.

To study the acute phase antibody response to SARS-CoV-2 infection and the persistence of antibodies in recovered COVID-19 patients, RBD-specific IgG/A/M levels were measured in sera from symptomatic (n=54), recovered (n=57) COVID-19 patients and control sera (n=26).

Antibody measurements were carried out in duplicates and each experiment was repeated independently twice with high reproducibility ( Figure S1 ). Antibody levels were calculated as the signal over mean signal obtained in the negative controls used in each microwell plate ( Figure 1A ). We observe that IgG/A/M levels in the symptomatic COVID-19 cohort, increases Follow up sera were collected from 11 symptomatic patients to monitor the antibody dynamics over time within each patient ( Figure 1B ). We observed a rapid increase in RBD-specific is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 25, 2020. . https://doi.org/10.1101/2020.08.23.20179796 doi: medRxiv preprint antibody levels within 10 DFS for all isotypes which plateaued or started to decline, approximately 15 DFS. RBD-specific IgG titers in recovered COVID-19 patients, were measured also in dilution series and calculated as the ratio between area under curve (AUC) and the mean AUC of control sera that was applied to each microwell plate. Utilizing in vitro neutralization assay as described previously 18 the nAb fraction out of the total RBD-specific antibodies was calculated. Each serum sample was applied to microwell plate w/ and w/o hACE2 as a competitive agent. Hence, the decrease of the signal is associated with the portion of nAbs that were depleted from the microwell due to blockade of epitopes on the RBD by hACE2 ( Figure S2 ). We found a strong correlation between the total RBD-specific antibodies and the nAb suggesting that measuring RBD-specific antibody levels can be used as a proxy to evaluate the nAbs levels ( Figure 1C ).

Collected clinical parameters for a subset of the recovered patients were stratified by the clinical indications. It was previously demonstrated that dyslipidemia and high blood pressure are linked to metabolic syndrome 19 . We found that both parameters were associated with the levels of anti-RBD IgG ( Figure 1D -E). C-reactive protein (CRP), hyperferritinemia and Ddimer were described as features of systemic inflammatory reactions in COVID-19 patients and were suggested to be used as an indication for disease severity 20-23 . Similar to the previous reports, we found that ferritin and CRP are correlated while ferritin and lymphocyte counts are inversely correlated ( Figure S3 ). We examined the association between these COVID-19 severity risk factors and the levels of RBD-specific antibodies. Both serum ferritin and CRP were found to be associated with high levels of anti-RBD IgG ( Figure 1F -G, Figure S4A -B) while elevated D-dimer was not found to be associated with increased levels of RBD-specific antibodies ( Figure S4C ). Age (n=52, Figure S5A ) and gender ( Figure S5B ) showed no, or weak correlation with RBD-specific IgG levels. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 25, 2020. . https://doi.org/10.1101/2020.08.23.20179796 doi: medRxiv preprint

To evaluate the persistence of anti-RBD antibodies following COVID-19 recovery, the antibody levels were tested for their association with DFS. We found that the antibody levels were inversely correlated with the DFS, indicating that they rapidly decay over time ( To monitor the B cell response in COVID-19 recovered patients and the association between RBD-specific B cell frequency with IgG levels, we applied PBMCs from recovered patients to FACS and isolated RBD-specific memory B cells (mBC) and plasmablasts (PB) using the double stain strategy ( Figure S6 ).

To this end, we calculated the frequency of RBD-specific mBC and PB out of the total CD19 + cell population and analyzed the correlation between the two B cell subsets and with DFS and RBD-specific antibody levels. In contrast to the decay identified for the serological memory as reflected by the RBD-specific IgG, we observed that RBD-specific mBC were stable over time (Figure 3A ). Follow up samples from a subset of the COVID-19 recovered patient cohort, demonstrated similar persistence of RBD-specific mBC and in some cases showing a mild increase of the RBD-specific mBCs frequency over time (Figure 3B ). These data suggest that the B cell memory compartment is stable for at least 6 months following the recovery from is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 25, 2020. . https://doi.org/10.1101/2020.08.23.20179796 doi: medRxiv preprint COVID-19. These results are in accordance with the general dynamics observed in the mBC compartment where once established, antigen-specific memory B cell populations are remarkably stable and highly enriched for quiescent and exceptionally long-lived cells antigenspecific mBC 25 .

It was recently reported that the B cell response following influenza vaccine does not induce long-lived plasma cells (LLPC) or these LLPC decline over time. Moreover, the associated influenza-specific antibodies decline in accordance with the LLPC frequency 26 . We hypothesized that the differentiation of B cells to become LLPC is impaired following SARS-CoV-2 infection as we observed that antigen-specific antibodies decline over time. To test this hypothesis, we studied the association between the frequency of RBD-specific PB subset and the frequency of RBD-specific mBC and found that the frequency of both subsets are highly correlated ( Figure 4A ). These data are consistent with the immunological mechanism governing the B cell response following affinity maturation including asymmetrical deviation of parent B cell post germinal center affinity maturation 27 . Next, we investigated the association between RBD-specific PB and the antibody levels as such association will suggest that the main contributor for the serum antibody levels are the short lived plasmablasts (SLPB).

Using linear regression analysis, we found an association between the RBD-specific IgG and the frequency of PB, suggesting that the contributor for serum IgG levels are mainly based on the presence of activated PB in the blood. In case LLPC were generated we would expect to find a decrease in PB frequency while a stable level of RBD-specific IgG.

The persistence of RBD-specific mBC suggests that the cellular arm of the adaptive immunity may provide robust recall immune response in case of re-infection however, the question remains -will this suffice in providing sufficient protection especially due to the decay of the is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 25, 2020. . https://doi.org/10.1101/2020.08.23.20179796 doi: medRxiv preprint serological memory? These aspects should be further investigated in follow up temporal studies when samples from recovered patients one year following onset of symptoms will be available. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 25, 2020. 

were measured by ELISA, as previously described 12, 29 with several modifications. Briefly, RBD-specific Ig levels in active patient sera were determined using 96 well ELISA plates that were coated overnight at 4°C with 2μg/ml RBD in PBS (pH 7.4). Next, coating solution was discarded and ELISA plates were blocked with 300µl of 3% w/v skim milk in PBS for 1 hour at 37⁰C. Following discarding blocking solution, duplicates of serum diluted 1:300 in 3% w/v skim milk in PBS were added to the wells. Negative control serum samples were also added in is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 25, 2020. . https://doi.org/10.1101/2020.08.23.20179796 doi: medRxiv preprint duplicates of 1:300 dilution. ELISA plates were washed three times with PBST and 50μl of horseradish peroxidase (HRP) conjugated anti-human IgG H+L / anti-human IgM / anti-human IgA secondary antibodies were added to each plate at the detection phase (50μl, 1:5000 ratio in 3% w/v skim milk in PBS) and incubated for 1 hour at room temperature (RT), followed by three washing cycles with 0.05% PBST. Developing was carried out by adding 50µl of TMB and reaction was quenched by adding 0.1M sulfuric acid. Plates were read using the Epoch Microplate Spectrophotometer ELISA plate reader using wave length of 450 and 620 nm.

The neutralization capacity of serum from recovered patients was determined using 96 well ELISA plates that were coated overnight at 4°C with 2μg/ml RBD in PBS (pH 7.4). Next, coating solution was discarded and ELISA plates were blocked with 300µl of 3% w/v skim milk in PBS for 1 hour at 37⁰C. Blocking solution was discarded and 50µl of 400nM hACE2 in 3% w/v skim milk were added to the positive hACE2 wells, and 3% w/v skim milk in PBS was added to the negative hACE2 wells for 1 hour at RT. Next, triplicates of 1:150 diluted serum samples w/ and w/o 400 nM hACE2 were added to the positive/negative hACE2 wells (respectively) and serially diluted 3-fold in 3% w/v skim milk in PBS (1:150-1:328,05 serum dilution factor). Negative serum samples were also added in duplicates of 1:150 dilution w/ and w/o 400nM hACE2. Plates were incubated for 1 hour at RT. ELISA plates were washed three times with PBST and 50μl of HRP conjugated anti-human IgG H+L secondary antibody were added at the detection phase (50μl, 1:5000 ratio in 3% w/v skim milk in PBS) and incubated for 1 hour at RT, followed by three washing cycles with 0.05% PBST. Developing was carried out by adding 50µl of TMB and reaction was quenched by adding 0.1M sulfuric acid. Plates were read using the Epoch Microplate Spectrophotometer ELISA plate reader using wave length of 450 and 620nm.

Flow cytometry analysis. PBMCs from COVID-19 recovered patients were stained for 15 minutes in cell staining buffer (BioLegend) at RT in the dark using the following antibodies:

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 25, 2020. The following B cell population was sorted using a BD Aria III cell sorter (BD Bioscience):

), mBC (CD19 + CD20 + CD27 var ) and RBD specific mBC (CD19 + CD20 + CD27 var RBD +(double stained) ). Gating strategy used for cell sorting was consistent throughout all samples, on singlets that were CD19+. B cells frequencies were calculated using FlowJo v10 software (BD, USA).

All curves were fitted on a sigmoidal dose-response curve and area under curve of each was calculated. Mann-Whitney test was used to compare continuous variables.

All reported P values were two-tailed, and a P value less than 0.05 were considered statistically significant. All statistics were performed with GraphPad Prism software (version 8, San Diego, California). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 25, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 25, 2020. . https://doi.org/10.1101/2020.08.23.20179796 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 25, 2020. . https://doi.org/10.1101/2020.08.23.20179796 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 25, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 25, 2020. . https://doi.org/10.1101/2020.08.23.20179796 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 25, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 25, 2020. Linear regression line is presented as a solid line. The association between D-dimer and RBDspecific antibodies was tested using nonparametic Mann-Whitney test. (ns p > 0.05).

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 25, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 25, 2020. . https://doi.org/10.1101/2020.08.23.20179796 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted August 25, 2020. . https://doi.org/10.1101/2020.08.23.20179796 doi: medRxiv preprint

A novel coronavirus outbreak of global health concern

The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance

A Novel Coronavirus from Patients with Pneumonia in China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A serological assay to detect SARS-CoV-2 seroconversion in humans

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients

Antibody responses to SARS-CoV-2 in patients with COVID-19

SARS-CoV-2 serological testing using electrochemiluminescence reveals a rapid onset of seroconversion in severe COVID-19 patients. medRxiv

Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19

T cells found in coronavirus patients 'bode well' for long-term immunity

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

Immunological memory and protective immunity: understanding their relation

Molecular Landscape of Anti-Drug Antibodies Reveals the Mechanism of the Immune Response Following Treatment With TNFalpha Antagonists

Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson's disease

Serum ferritin as an independent risk factor for severity in COVID-19 patients

Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells

Plasma CRP level is positively associated with the severity of COVID

D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study

Competence and competition: the challenge of becoming a longlived plasma cell

Cellular Dynamics of Memory B Cell Populations: IgM+ and IgG+ Memory B Cells Persist Indefinitely as Quiescent Cells

Influenza vaccine-induced human bone marrow plasma cells decline within a year after vaccination

Antibodies and B cell memory in viral immunity

Quantitation of rare memory B cell populations by two independent and complementary approaches

Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients

PBMCs were enriched for B cells by negative selection using EasySep magnetic beads followed by FACS to isolate antigen-specific mBC (upper panel -CD19 + CD20 + CD27 var RBD double positive ) and antigen-specific plasmablasts (lower panel -CD19 + CD20 -CD27 high CD38 high RBD double positive ). Frequencies of B cell subsets were calculated per total CD19 + B cells

07% (n=17) 48.3% (n=29) Male 67.93% (n=36) 51.7% (n=31) Median DFS 13 (0-60)

Ferritin (µg/mL) NA

Underlying medical conditions Hypertension NA 39.6% (n=48)

Dyslipidemia NA 41.7% (n=48)

We wish to thank Prof. Itai Benhar and Dr. Limor Nahary from the Shmunis school of Biomedicine and cancer research, Tel Aviv University, for their assistance in providing the initial RBD and hACE2 reagents, Dr. Ronit Rosenfeld from the Israel Institute for Biological Research (IIBR) for her generous assistance and Prof. Mordechai Gerlic and Prof. Ariel Munitz from the Sackler Faculty of medical, Tel Aviv University.